Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
View Patent ↗The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.
1. A pharmaceutical composition comprising a milled mixture of (a) crystalline anhydrous monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate exhibiting an X-ray powder diffraction pattern having a peak at 2.98±0.2° 2Θ and (b) at least one active agent, wherein the active agent is a peptide.
2. The pharmaceutical composition of claim 1 , wherein the crystalline anhydrous monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate further exhibits X-ray powder diffraction pattern peaks at 14.53, 15.72, and 26.36±0.2° 2Θ.
3. The pharmaceutical composition of claim 1 , wherein the milled mixture further comprises a pharmaceutically acceptable additive.
4. The pharmaceutical composition of claim 1 , wherein the mixture comprises at least 50% by weight of the crystalline monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate, based on the total weight of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate in the pharmaceutical composition.
5. The pharmaceutical composition of claim 1 , wherein the mixture comprises at least 90% by weight of the crystalline monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate, based on the total weight of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate in the pharmaceutical composition.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a tablet.
7. The pharmaceutical composition of claim 6 , wherein the tablet is prepared by direct compression.
8. The pharmaceutical composition of claim 1 , wherein the X-ray powder diffraction pattern of the composition further exhibits peaks at 6.69, 13.58 and 16.80±0.2° 2Θ.
9. A pharmaceutical composition comprising a milled mixture of (a) crystalline anhydrous monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate exhibiting a melting point onset at about 198° C. according to differential scanning calorimetry and (b) at least one active agent, wherein the active agent is a peptide.
10. The pharmaceutical composition of claim 9 , wherein the milled mixture further comprises a pharmaceutically acceptable additive.
11. The pharmaceutical composition of claim 9 , wherein the mixture comprises at least 50% by weight of the crystalline monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate, based on the total weight of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate in the pharmaceutical composition.
12. The pharmaceutical composition of claim 9 , wherein the mixture comprises at least 90% by weight of the crystalline monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate, based on the total weight of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate in the pharmaceutical composition.
13. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is a tablet.
14. The pharmaceutical composition of claim 13 , wherein the tablet is prepared by direct compression.
15. The pharmaceutical composition of claim 9 , wherein the X-ray powder diffraction pattern of the composition exhibits peaks at 2.98, 6.69, 13.58 and 16.80±0.2° 2Θ.
16. A process for preparing a pharmaceutical composition comprising wet granulating monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate exhibiting an X-ray powder diffraction pattern having a peak at 2.98±0.2° 2Θ with or without one or more active agents and/or pharmaceutically acceptable additives.
17. A process for preparing a pharmaceutical composition comprising wet granulating monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate exhibiting a melting point onset at about 198° C. according to differential scanning calorimetry with or without one or more active agents and/or pharmaceutically acceptable additives.
18. The process of claim 16 , wherein the monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate in the wet granulated composition exhibits an X-ray powder diffraction pattern having peaks at 6.69, 13.58 and 16.80±0.2° 2Θ.
19. The process of claim 17 , wherein the monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate in the wet granulated composition exhibits an X-ray powder diffraction pattern having peaks at 6.69, 13.58 and 16.80±0.2° 2Θ.
20. The process of claim 16 , wherein the wet granulation step is performed with an active agent, wherein the active agent is a peptide.
21. The process of claim 17 , wherein the wet granulation step is performed with an active agent, wherein the active agent is a peptide.
22. A pharmaceutical composition prepared by a process according to claim 20 .
23. A pharmaceutical composition prepared by a process according to claim 21 .